pertensives in this patient population. However, the
Introduction hypertension or renal impairment.
CsA has an oral absolute bioavailability in the range Cyclosporin (CsA) is a powerful immunosuppressant of 27-77% [21, 22] . It is virtually completely metabwidely used in organ-transplant patients to prevent olized and has a mean oral clearance of about 59 l/h rejection. As many as 80% of patients receiving long-and has a steady-state volume of distribution of about term CsA therapy have elevated blood pressure [1], 130-190 litres. [22] . Disposition half-life is approxiand calcium antagonists (CAs) are often used as antihymately 5.6 h [22] . In whole blood, 50-60% of cyclosporin accumulates in erythocytes. Leukocytes also avidly the circulation associated with plasma lipoproteins [23] . Consequently, blood concentrations are clinically more relevant than plasma concentrations. Mibefradil is both a substrate for and an inhibitor of cytochrome P-450 (CYP) 3A4, which is the enzyme primarily responsible for CsA metabolism [21, 24, 25] . CsA intestinal metabolism (predominantly gut wall ) by CYP3A4 is about twice that of hepatic first-pass metabolism [21] . Inhibitors of CYP3A4 generally inhibit both sites of enzymatic activity during the absorption/hepatic first-pass process. This is especially Fig. 1 . The study design. relevant for CsA, since it is virtually completely metabolized, with less than 1% of a dose recovered intact in dosage had been chosen to ensure graft function and survival.
urine [23] . Ketoconazole, another inhibitor of
The selected starting dose of mibefradil was 25 mg; prelimin-CYP3A4, increases CsA oral bioavailability approxiary studies have shown this to be well tolerated and at the mately 2.5-fold and reduces systemic clearance to an low end of the dose-response curve. On the first day of the average of 56% of its original value [26 ] . Recently, it study, patients were administered one 25-mg mibefradil tablet has been shown that intestinal P-glycoprotein, a pro-between 7 a.m. and 9 a.m., and on days 2-7, the dosage was tein able to transport cyclosporin, plays a significant increased to one 50-mg mibefradil tablet daily. Compliance role in the first-pass elimination of cyclosporin. Drug was established by tablet counts and blood/plasma concentrainteractions with cyclosporin previously ascribed to tions. Two patients participated for only 6 days. No changes intestinal CYP3A4 may instead be mediated by inter-were made in concomitant drug therapy, including CsA.
Trough CsA blood concentrations (C min ) were measured 12 h actions with intestinal P-glycoprotein. [27] post-dose on Days 2, 5, and 6. On Day 6 or Day 7, a full
The present study was undertaken to assess the baseline profile. One additional blood sample was taken to capture 24-h mibefradil plasma concentrations. Mibefradil tablets were equivalent to the commercial for-
Subjects and methods
mulation. CsA was taken as commercially available SandimmunA capsules (25 and/or 100 mg) or solution Three white men and three white women without childbearing (100 mg/ml ) in accordance with patients' individualized potential, mean age 61 years (range 42-68), with stable renal dosage schedules. allograft transplants and mild-to-moderate hypertension, Blood samples (EDTA anticoagulated ) were assayed for receiving stable doses of CsA, entered the study. Four CsA concentration and plasma mibefradil. CsA blood conpatients completed 7 days of treatment and the follow-up on centrations were measured by fluorescence polarization Day 8, but because of concern for patient safety, two patients immunoassay using a commercially available kit (TDxA received 6 days of treatment and had the follow-up on Day Immunosuppressant Drug Assay-CsA Monoclonal in 7. Patients' renal transplantation had occurred more than 6 Whole Blood, Abbott Laboratories, Abbott Park, Illinois, months before the start of the study, transplant function had USA) having a lower limit of quantitation of 25 ng/ml. This been stable 2 months before the start of the study, and CsA assay does exhibit some metabolite cross-reactivity, although doses and blood concentrations had been stable for at least it is generally low. Mibefradil plasma concentrations were 1 month before the start of the study. Patients were excluded measured by a specific and accurate high-performance liquid if they (a) were receiving concomitant medications that could chromatography method with fluorescence detection, having affect CsA plasma concentrations; (b) had had immunolo-a lower limit of quantitation of approximately 8.5 ng/ml. gically related loss of a previous transplant within 12 months Vital signs, routine laboratory variables, electrocardioof transplantation; (c) had had vascular rejection of a grams, and biochemical parameters were assessed at the transplant within 6 months; and (d ) had malignant hyperten-prestudy screening and at follow-up on Day 7 or 8. sion, major systemic disease, or histories of alcohol or drug Additional measurements for serum creatinine were conabuse. The study, conducted in Switzerland, was approved ducted on Days 2, 5, and 7. by the local ethics committees and conducted in accordance CsA C min and steady-state maximum (C max ) blood concenwith the principles of the Declaration of Helsinki as amended trations and the time of the maximum blood concentration in Tokyo, Venice, and Hong Kong. All patients enrolled in (T max ) were determined from the data. Steady-state area the study gave written informed consent.
under the CsA blood concentration-time curve from 0 to The overall design of this open-label study is summarized 11 h (AUC 0-11 h ) was calculated by the trapezoidal rule. in Figure 1 . Two days before enrollment, patients receiving Parameters were compared using the paired t test. twice-daily CsA (SandimmunA, Sandoz) and under treatment for hypertension had one of their antihypertensive medications withdrawn. On the following day, 1 day before the Results study began, patients were screened for eligibility, and a baseline 11-h steady-state CsA blood concentration-time In addition to CsA, some patients also received other profile was obtained following drug ingestion with 100 ml immunosuppressive therapy. One received prednisone, tap water. Samples were obtained at −0.5, 0.5, 1, 2, 4, 6, and 11±2 h after the first of their two daily CsA doses. CsA another azathioprine, and a third prednisone and azathioprine. Morning and evening doses of CsA with 40 mg oral frusemide for 2 days. Other adverse events judged related to treatment were frequent urinaremained constant from Day 1 to Day 6 for all patients. Individual doses varied from 50 mg morning and even-tion, muscle cramps, increased appetite, constipation, flushing, facial oedema, and dizziness. There were no ing to 175 mg in the morning and 150 mg in the evening. Five patients had essential hypertension and serious adverse events.
No marked laboratory abnormalities occurred one had secondary hypertension. At study entry, three patients were taking no antihypertensive medications, during the study. However, one patient experienced an increase from baseline with coadministration of mibefwhereas the other three were taking from one to three antihypertensive drugs, none of which was known to radil in both serum creatinine (132 vs 166 mmol/l ) and blood urea nitrogen (11.7 vs 16.5 mmol/l ) at followaffect CsA plasma concentrations.
Individual and mean pharmacokinetic parameter up on Day 8. Steady-state trough and peak CsA blood concentrations increased approximately two-and values for CsA with and without mibefradil coadministration are summarized in Table 1 . The blood CsA threefold following mibefradil addition for this patient.
The investigators judged this deterioration of kidney concentration-time profile of a single subject is illustrated in Figure 2 . On the last day of the study, C min function to be caused by a mibefradil-induced enhancement of CsA blood concentrations to toxic levels. increased an average of 2.7-fold in the presence of mibefradil; mean C max increased 2.1-fold, and AUC 0-11 Before mibefradil treatment, median heart rate was 70. was 84 mmHg (range 75-88 mmHg) and median sitting concentration-time profile on the last study day is illustrated in Figure 3 .
systolic BP was 144.5 mmHg (range 137-169 mmHg). At the end of mibefradil treatment, median sitting The most frequent adverse event was pedal oedema, reported by three patients, one of whom was treated diastolic BP was 79.5 mmHg (range 68-84 mmHg) and median sitting systolic BP was 135.5 mmHg (range 129-141 mmHg). No clinically relevant electrocardiographic changes were seen in this study, and the mean PQ and QT intervals were unchanged. As noted previously, four of the six patients completed the full 7-day mibefradil treatment. No CsA toxicity was observed in the two patients who ended the study early as judged by stable serum creatinine concentrations.
Discussion
This was the first investigation of the interaction between mibefradil and CsA. After 6 or 7 days of ive dose of mibefradil (50 mg after the first day), CsA
Other CAs also interact with CsA, including verapamil [31] , diltiazem [32] , and nicardipine [33] , while concentrations increased two-to threefold over baseline levels (P<0.02). Coadministration of CsA with among the dihydropyridine CAs (nifedipine, nitrendipine, isradipine, and amlodipine), clinically relevant mibefradil had no substantial effect on mibefradil plasma concentrations, since mibefradil profiles corre-increases in CsA concentrations are not observed [30, [34] [35] [36] [37] [38] . However, diltiazem and verapamil increase sponded to those observed with mibefradil monotherapy [18] .
CsA concentrations less than 50% [4] , whereas moderate-dose mibefradil increases CsA blood levels two-to One patient developed CsA toxicity and experienced a deterioration in kidney function, as indicated by threefold. The elevation of CsA blood concentrations by other CAs has been explained by an analogous increased serum creatinine and blood urea nitrogen. This finding following 7 days of mibefradil treatment metabolism-inhibition mechanism [30, 39] .
CsA elimination is an excellent model for the in vivo emphasizes the importance of appropriate CsA monitoring during mibefradil therapy. Other adverse events study of CYP 3A4 activity [28] . The finding that 50-mg daily doses of mibefradil elevate steady-state CsA AUC in this short-term study were of mild-to-moderate severity. No clinically relevant changes in BP and heart by an average of 2.3-fold confirms that mibefradil has significant CYP3A4 inhibitory activity. Mibefradil rate were seen with added mibefradil, although there was a trend toward decreased sitting systolic BP. No blood concentrations were not affected by concomitant administration of CsA. This has the important pracclinically relevant electrocardiographic changes were seen.
tical consequence that no adjustment of the mibefradil dose is necessary for patients receiving CsA. Mibefradil, its hydrolyzed metabolite (Ro 40-5966), and CsA [21, 24, 25, 28] are all substrates for CYP3A4.
Although the interaction of mibefradil with CsA may at first be seen as a drawback in transplant Additionally, mibefradil and Ro 40-5966 are inhibitors of the CYP3A4 isoenzyme. It is therefore likely that patients, it could have positive economic value by substantially decreasing the high cost of CsA therapy. the elevated CsA blood concentrations observed with concomitant mibefradil administration were due to Ketoconazole has previously been used for this purpose, but mibefradil may be a more attractive alternatmibefradil inhibition of CYP3A4 in the gut and liver, analogous to inhibition of the same isoenzyme by ive, since it could offer an independent therapeutic contribution in these patients [1] . If CsA and mibefraketoconazole [26 ] . The CsA blood assay used in this study was a fluorescence polarization immunoassay dil are administered concomitantly, a reduced CsA dose and initially frequent monitoring of CsA blood utilizing a monoclonal antibody. Although this assay does exhibit some low metabolite cross-reactivity, it concentrations are necessary. Similarly, if mibefradil were discontinued, monitoring of CsA blood concendoes not provide a realistic metric for CsA metabolite blood concentrations. Co-therapy with CAs can change trations and an upward adjustment of the CsA dose would probably be necessary. the metabolite profile of CsA [3, 5, 29, 30] . Although some of CsA's approximately 30 metabolites apparently have an immunosuppressive effect others may increase nephrotoxicity associated with CsA [3, 29, 30] . References Inasmuch as CsA blood metabolites were not quantitated in this study, it is not possible to assess their
